The Oncology Institute Announces New Leaders to Oversee Technology and Clinical Trials
The Oncology Institute Announces New Leaders to Oversee Technology and Clinical Trials
In her new role as Vice President of Clinical Research, Ms. Green will oversee the clinical research arm of TOI and expand access to clinical trials for TOI patients. Ms. Green's clinical research experience spans over 24 years across several different areas including data management, project management, clinical operations, and functional leadership. Most recently, she held roles at Labcorp Drug Development spearheading transformational initiatives for the conduct of clinical trials, including mobile health, decentralized clinical trials, and other study design innovations via data, technology, and process optimization. Ms. Green also led large multi-country based clinical operations teams during her tenure as Executive Director for Latin America from 2015–2017 and Executive Director for North America from 2011–2015.Phil Reger and Cristina Green Will Serve as the Chief Information Officer and Vice President of Clinical Research, Respectively
菲爾·裏格爾和克里斯蒂娜·格林將分別擔任臨牀研究的首席信息官和副總裁
CERRITOS, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, is pleased to announce the hiring of two new executives. Phil Reger will serve as the Chief Information Officer and Cristina Green will serve as the Vice President of Clinical Research.
加利福尼亞州塞裏託斯，2022年10月11日(環球通訊社)--美國最大的基於價值的腫瘤學組織之一腫瘤研究所，Inc.(納斯達克：TOI)高興地宣佈招聘兩名新高管。菲爾·裏格爾將擔任首席信息官，克里斯蒂娜·格林將擔任臨牀研究副總裁。
As Chief Information Officer, a newly created position, Mr. Reger will lead enterprise-wide technology and data initiatives, developing strategies to support TOI's growth. Mr. Reger's professional experience includes 25 years of IT experience in high-growth environments, with 20 of them specializing in healthcare. Before joining TOI, Mr. Reger was part of the founding team that launched Radiology Partners, the largest radiology practice in the United States. As CTO, he launched and grew an IT department that met business demands for high levels of acquisitive growth, reliable clinical systems, and advanced capabilities. Most recently, he partnered with visionary clinicians and data scientists to develop an artificial intelligence platform enabling physicians to deliver industry-leading levels of patient care. Prior to Radiology Partners, he served as a key member of the DaVita IT leadership team.
作為首席信息官這一新設立的職位，雷傑先生將領導企業範圍的技術和數據計劃，制定支持TOI增長的戰略。雷傑先生的專業經驗包括在高增長環境中的25年IT經驗，其中20年是醫療保健方面的專業經驗。在加入TOI之前，雷傑先生是創辦Radiology Partners的創始團隊的一員，Radiology Partners是美國最大的放射學診所。作為首席技術官，他創辦並發展了一個IT部門，以滿足企業對高水平的收購增長、可靠的臨牀系統和高級功能的需求。最近，他與富有遠見的臨牀醫生和數據科學家合作，開發了一個人工智能平臺，使醫生能夠提供行業領先的患者護理水平。在加入Radiology Partners之前，他是DaVita IT領導團隊的關鍵成員。
In her new role as Vice President of Clinical Research, Ms. Green will oversee the clinical research arm of TOI and expand access to clinical trials for TOI patients. Ms. Green's clinical research experience spans over 24 years across several different areas including data management, project management, clinical operations, and functional leadership. Most recently, she held roles at Labcorp Drug Development spearheading transformational initiatives for the conduct of clinical trials, including mobile health, decentralized clinical trials, and other study design innovations via data, technology, and process optimization. Ms. Green also led large multi-country based clinical operations teams during her tenure as Executive Director for Latin America from 2015–2017 and Executive Director for North America from 2011–2015.
在擔任臨牀研究部副總裁的新職務後，王志浩將負責TOI的臨牀研究部門，並擴大TOI患者參與臨牀試驗的機會。格林女士擁有超過24年的臨牀研究經驗，涉及多個不同領域，包括數據管理、項目管理、臨牀運營和職能領導。最近，她在Labcorp藥物開發公司擔任職務，帶頭開展臨牀試驗的轉型計劃，包括移動醫療、分散臨牀試驗和其他通過數據、技術和流程優化實現的研究設計創新。在2015年至2017年擔任董事拉丁美洲首席執行官和2011年至2015年擔任北美區首席執行官期間，格林女士還領導了多個國家的大型臨牀運營團隊。
TOI's CEO Brad Hively commented, "TOI thrives on incredible leadership, and I couldn't be more excited about these two seasoned leaders joining our team. The roles that Phil and Cristina fill are especially vital as we enhance our focus on research, technology, and health equity. I am confident that their contributions will help us advance even further."
TOI的首席執行官布拉德·海弗利評論説：“TOI依靠令人難以置信的領導力而蓬勃發展，我對這兩位經驗豐富的領導者加入我們的團隊感到無比興奮。在我們加強對研究、技術和醫療公平的關注之際，菲爾和克里斯蒂娜所扮演的角色尤為重要。我相信他們的貢獻將幫助我們進一步發展。”
About The Oncology Institute
關於腫瘤學研究所
Founded in 2007, The Oncology Institute of Hope and Innovation (TOI) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of approximately 1.6 million patients including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced healthcare organizations. With 80+ employed clinicians and more than 600 teammates in more than 50 clinic locations and growing, TOI is changing oncology for the better. For more information visit .
成立於2007年的希望與創新腫瘤學研究所(TOI)通過在社區環境中提供高度專業化的、基於價值的癌症護理來推動腫瘤學的發展。TOI為大約160萬名患者提供基於證據的尖端癌症護理，包括臨牀試驗、輸血和其他傳統上與最先進的醫療機構相關的護理提供模式。擁有80多名受僱的臨牀醫生和500多名隊友，分佈在50多個診所，而且還在不斷增長，TOI正在讓腫瘤學變得更好。有關更多信息，請訪問。
Contacts
聯繫人
Media
The Oncology Institute
Julie Korinke
JulieKorinke@theoncologyinstitute.com
(562) 735-3226 x 88806
媒體
腫瘤學研究所
朱莉·科林克
郵箱：JulieKorinke@theoncologyInstitute te.com
(562) 735-3226 x 88806
Juan Lezama
juanlezama@theoncologyinstitute.com(562) 374-8434
胡安·萊扎馬
郵箱：juanlezama@theoncologyInstitute te.com(562)374-8434
Investors
Solebury Trout
Maria Lycouris
mlycouris@soleburytrout.com
投資者
索爾伯裏鮭魚
瑪麗亞·呂庫利斯
郵箱：mlyCouris@soleburyrout.com